Skip to contentpdufa.bio

GX-03 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

GX-03 Phase is a Turn Therapeutics Inc. program in moderate to severe atopic dermatitis. Its next catalyst is a Readout in Q1 2027.

TTRX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Moderate to severe atopic dermatitis. Sponsor: Turn Therapeutics Inc. (TTRX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027TTRX

Questions

When is GX-03 Phase's next FDA decision or readout?

The next tracked catalyst for GX-03 Phase is a Readout in Q1 2027.

What happened at GX-03 Phase's most recent FDA decision?

No FDA decision for GX-03 Phase is in our archive yet.

What is GX-03 Phase used for?

In our records GX-03 Phase is under review or in development for Moderate to severe atopic dermatitis.

Who makes GX-03 Phase?

Turn Therapeutics Inc. (TTRX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.